Gastroparesis is a disorder affecting people with type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).&nbsp;
&nbsp;
Diabetic Gastroparesis (DGP) is a severe complication of diabetes, which results in delayed gastric emptying with associated upper gastrointestinal symptoms in the absence of any mechanical obstruction.
&nbsp;
Diabetic Gastroparesis Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Diabetic Gastroparesis in 7MM from 2017 to 2030 is segmented as:-&nbsp;
&nbsp;
<ul>
<li>Total Prevalent Cases of Diabetic Gastroparesis</li>
<li>Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus</li>
<li>Prevalence of Diabetic Gastroparesis based on Gender</li>
<li>Prevalence of Symptoms associated with Diabetic Gastroparesis&nbsp;</li>
</ul>
&nbsp;
Diabetic Gastroparesis Epidemiology&nbsp;
<ul>
<li>The total Diabetic Gastroparesis prevalent population in the 7MM is expected to rise to&nbsp;17,859,995&nbsp;by 2030.&nbsp;&nbsp;</li>
<li>About&nbsp;40%&nbsp;of patients with Type 1 Diabetes have Gastroparesis.</li>
<li>Around&nbsp;30%&nbsp;of Type 2 Diabetes Mellitus (DM) cases suffer from Diabetic Gastroparesis.</li>
<li>The prevalence of both T1DM and T2DM associated Diabetic Gastroparesis was highest in the United States.&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size" target="_blank" rel="noopener noreferrer">Diabetic Gastroparesis Market</a>
The Market Size of Diabetic Gastroparesis in the 7MM is expected to reach USD&nbsp;4331.47&nbsp;million by 2030.
&nbsp;
Diabetic Gastroparesis Market Drivers
<ul>
<li>Untapped market</li>
<li>Increased awareness</li>
<li>Novel therapeutic options</li>
<li>Advances in Continuous Glucose Monitoring (CGM) techniques</li>
</ul>
&nbsp;
Diabetic Gastroparesis Market Barriers
<ul>
<li>Impaired quality of life</li>
<li>Crude epidemiological data</li>
<li>Treatment associated barriers</li>
<li>Disease-associated burden</li>
</ul>
&nbsp;
Diabetic Gastroparesis Emerging Drugs
The emerging drugs of the Diabetic Gastroparesis market are&nbsp;
<ul>
<li>Relamorelin&nbsp;</li>
<li>Metoclopramide Nasal Spray (Gimoti)&nbsp;&nbsp;</li>
<li>Velusetrag&nbsp;&nbsp;</li>
<li>Sepiapterin (CNSA-001)&nbsp;&nbsp;&nbsp;</li>
<li>CIN-102&nbsp;&nbsp;</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Diabetic Gastroparesis Key Players
The key players in the Diabetic Gastroparesis market are
<ul>
<li>Allergan</li>
<li>Evoke Pharma Inc</li>
<li>Theravance Biopharma</li>
<li>Censa Pharmaceuticals</li>
<li>CinDome Pharma</li>
</ul>
And many others.&nbsp;

Diabetic Gastroparesis Market

Diabetic Gastroparesis Symptions, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.